Related Experiment Video
Updated: Oct 13, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Locked and loaded: strong TCR signaling primes anti-PD-1 therapy
Kristina Correa1, Michael L Dustin1
1Kennedy Institute of Rheumatology, Nuffield Department of Rheumatology, Orthopedics, and Musculoskeletal Sciences, The University of Oxford, Oxford OX3 7FY, UK.
Abstract:
With continuous T cell receptor (TCR) signaling, T cells can attenuate subsequent antigen responses through adaptive tolerance, thus averting autoimmunity, but potentially also providing refuge to developing cancers. Elliot and coworkers add to our understanding of adaptation via immune checkpoints by exploiting accelerated in vivo adaptive tolerance in the face of strong TCR signaling.
Related Concept Videos
Tumor Immunotherapy
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Targeted Cancer Therapies
There are several types of targeted therapies against...

